drugset / Trial / NCT02582359
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
Phase 1
Completed
39 enrolled
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabine as a possible treatment for the patient AML.
Timeline
- Start
- 2016-01
- Primary completion
- 2022-04
- Completion
- 2022-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 1.5 mg | Oral |
| Subject | Ixazomib | Unknown | 2.3 mg | Oral |
| Subject | Ixazomib | Unknown | 3 mg | Oral |
| Background | Cytarabine | Small molecule | 100 mg/m2 | — |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | — |
| Background | Daunorubicin | Small molecule | 60 mg/m2 | Intravenous |